Literature DB >> 25370894

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

Andrea Tendas1, Maria Felicita Lissia, Daniela Piccioni, Liliana Tirimbelli, Laura Scaramucci, Marco Giovannini, Teresa Dentamaro, Alessio Perrotti, Paolo de Fabritiis, Pasquale Niscola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25370894     DOI： 10.1007/s00520-014-2502-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  10 in total

1.  Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

Authors:  John F Seymour; Pierre Fenaux; Lewis R Silverman; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Alan F List; Steven D Gore; Jay Backstrom; David McKenzie; C L Beach
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-06       Impact factor: 6.312

2.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

Authors:  Lewis R Silverman; Pierre Fenaux; Ghulam J Mufti; Valeria Santini; Eva Hellström-Lindberg; Norbert Gattermann; Guillermo Sanz; Alan F List; Steven D Gore; John F Seymour
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

3.  Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.

Authors:  M T Voso; L Fianchi; M Criscuolo; M Greco; F D'Alo; S Hohaus; L Pagano; G Leone
Journal:  Leuk Res       Date:  2011-09-09       Impact factor: 3.156

4.  Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Authors:  Massimo Breccia; Maria Teresa Voso; Luca Maurillo; Pasquale Niscola; Luana Fianchi; Maria Antonietta Aloe Spiriti; Francesco Buccisano; Roberto Latagliata; Sabrina Pelliccia; Susanna Fenu; Andrea Tendas; Giuliana Alimena
Journal:  Am J Hematol       Date:  2014-02-28       Impact factor: 10.047

5.  Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Authors:  Maria Teresa Voso; Massimo Breccia; Monia Lunghi; Antonella Poloni; Pasquale Niscola; Carlo Finelli; Alessia Bari; Pellegrino Musto; Renato Zambello; Luana Fianchi; Giuliana Alimena; Giuseppe Leone
Journal:  Eur J Haematol       Date:  2013-02-28       Impact factor: 2.997

6.  Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS.

Authors:  Francesca Pierdomenico; Susana Esteves; Antonio Almeida
Journal:  Ann Hematol       Date:  2013-04-21       Impact factor: 3.673

7.  Transfusions at home in patients with myelodysplastic syndromes.

Authors:  Pasquale Niscola; Andrea Tendas; Marco Giovannini; Luca Cupelli; Malgorzata Monika Trawinska; Massimiliano Palombi; Laura Scaramucci; Gregorio Antonio Brunetti; Alessio Perrotti; Benedetta Neri; Fabio Efficace; Claudio Cartoni; Paolo de Fabritiis; Franco Mandelli
Journal:  Leuk Res       Date:  2012-02-14       Impact factor: 3.156

8.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.

Authors:  Andrea Tendas; Luca Cupelli; Agostina Siniscalchi; Laura Scaramucci; Marco Giovannini; Teresa Dentamaro; Alessio Perrotti; Tommaso Caravita; Paolo de Fabritiis; Pasquale Niscola
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-16       Impact factor: 2.576

10.  Managing myelodysplastic syndromes in very old patients: a teaching case report.

Authors:  Pasquale Niscola; Massimiliano Palombi; Malgorzata Monika Trawinska; Andrea Tendas; Marco Giovannini; Laura Scaramucci; Alessio Perrotti; Paolo de Fabritiis
Journal:  Clin Interv Aging       Date:  2013-04-11       Impact factor: 4.458
  10 in total
  2 in total

1.  Oral hypomethylating agents: beyond convenience in MDS.

Authors:  Elizabeth A Griffiths
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Azacitidine in outpatient treatment - single center experience.

Authors:  Justyna Rybka; Ewa Stefanko; Aleksandra Bogucka-Fedorczuk; Aleksandra Butrym; Rafał Poręba; Kazimierz Kuliczkowski; Tomasz Wróbel
Journal:  Contemp Oncol (Pozn)       Date:  2016-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.